Mechanically Optimizing Cardiac Preload in Heart Failure Patients
Overview
The purpose of the current study is to determine if partial balloon occlusion of the inferior vena cava can optimize cardiac pre-load and subsequently pulmonary pressures and cardiac output as a novel method to unload pulmonary edema and other symptoms of decompensated congestive heart failure. All products in this study are FDA approved and adhere to the specifications of the intended use.
Full Title of Study: “Mechanically Optimizing Cardiac Preload Using Partial Inferior Vena Cava Occlusion to Reduce Pulmonary Pressures in Heart Failure Patients in Heart Failure Patients”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: June 30, 2024
Interventions
- Diagnostic Test: Partial IVC occlusion
- Partial balloon occlusion of the inferior vena cava.
Arms, Groups and Cohorts
- HF patients
- Decompensated heart failure patients undergoing right heart catheterization.
Clinical Trial Outcome Measures
Primary Measures
- Change in pulmonary arterial pressures
- Time Frame: During partial balloon occlusion
- Change in the measured mean pulmonary arterial pressure
Secondary Measures
- Change in cardiac output
- Time Frame: During partial balloon occlusion
- Change in cardiac output measured in liters per minute
Participating in This Clinical Trial
Inclusion Criteria
1. Subjects scheduled to undergo a right heart catheterization at Saint Thomas Hospital. 2. New York Heart Association (NYHA) II or III. 3. Subjects must be last least 18 years of age. 4. A left ventricular ejection fraction >= 20%. 5. Pulmonary artery occlusion pressure, or pulmonary wedge pressure >20 mmHg. Exclusion Criteria:
1. Subjects without sinus rhythm. 2. Evidence of right heart failure. 3. Patients with primary pulmonary hypertension 4. Pulmonary wedge pressure <15mmHg. 5. Significant lung disease, such as prior diagnosis of COPD. 6. Resting or dynamic outflow tract gradient 7. Patients with left bundle branch block
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 80 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Cardioflow Technologies, LLC
- Collaborator
- Saint Thomas Health
- Provider of Information About this Clinical Study
- Sponsor
- Overall Contact(s)
- Daniel W Kaiser, MD, 6154152586, dan@cardioflowtech.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.